[1]

Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, et al. 2025. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduction and Targeted Therapy 10:210

doi: 10.1038/s41392-025-02269-w
[2]

DiNardo CD, Erba HP, Freeman SD, Wei AH. 2023. Acute myeloid leukaemia. The Lancet 401:2073−2086

doi: 10.1016/S0140-6736(23)00108-3
[3]

Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, et al. 2021. Acute myeloid leukemia: current progress and future directions. Blood Cancer Journal 11:41

doi: 10.1038/s41408-021-00425-3
[4]

June CH, Sadelain M. 2018. Chimeric antigen receptor therapy. New England Journal of Medicine 379:64−73

doi: 10.1056/nejmra1706169
[5]

Uslu U, Castelli S, June CH. 2024. CAR T cell combination therapies to treat cancer. Cancer Cell 42:1319−1325

doi: 10.1016/j.ccell.2024.07.002
[6]

Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, et al. 2023. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nature Reviews Clinical Oncology 20:49−62

doi: 10.1038/s41571-022-00704-3
[7]

Cao W, Xing H, Li Y, Tian W, Song Y, et al. 2022. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomarker Research 10:38

doi: 10.1186/s40364-022-00385-1
[8]

Jiang H, Shi Z, Wang P, Wang C, Yang L, et al. 2019. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. JNCI: Journal of the National Cancer Institute 111:409−418

doi: 10.1093/jnci/djy134
[9]

Qi C, Gong J, Li J, Liu D, Qin Y, et al. 2022. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Medicine 28:1189−1198

doi: 10.1038/s41591-022-01800-8
[10]

Tang L, Pan S, Wei X, Xu X, Wei Q. 2023. Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Molecular Therapy 31:3146−3162

doi: 10.1016/j.ymthe.2023.09.021
[11]

Shi H, Li A, Dai Z, Xue J, Zhao Q, et al. 2023. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models. Frontiers in Immunology 14:1165404

doi: 10.3389/fimmu.2023.1165404
[12]

Li HS, Israni DV, Gagnon KA, Gan KA, Raymond MH, et al. 2022. Multidimensional control of therapeutic human cell function with synthetic gene circuits. Science 378:1227−1234

doi: 10.1126/science.ade0156
[13]

Luo H, Su J, Sun R, Sun Y, Wang Y, et al. 2020. Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion. Clinical Cancer Research 26:5494−5505

doi: 10.1158/1078-0432.CCR-20-0777
[14]

Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, et al. 2018. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nature Biotechnology 36:346−351

doi: 10.1038/nbt.4086
[15]

Lu Y, Hong S, Li H, Park J, Hong B, et al. 2012. Th9 cells promote antitumor immune responses in vivo. Journal of Clinical Investigation 122:4160−4171

doi: 10.1172/JCI65459
[16]

Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, et al. 2012. Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells. Nature Medicine 18:1248−1253

doi: 10.1038/nm.2856
[17]

Ma X, Bi E, Huang C, Lu Y, Xue G, et al. 2018. Cholesterol negatively regulates IL-9–producing CD8+ T cell differentiation and antitumor activity. Journal of Experimental Medicine 215:1555−1569

doi: 10.1084/jem.20171576
[18]

de Visser KE, Joyce JA. 2023. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41:374−403

doi: 10.1016/j.ccell.2023.02.016
[19]

Zhong L, Li Y, Muluh TA, Wang Y. 2023. Combination of CAR-T cell therapy and radiotherapy: opportunities and challenges in solid tumors (Review). Oncology Letters 26:281

doi: 10.3892/ol.2023.13867
[20]

Xia X, Yang Z, Lu Q, Liu Z, Wang L, et al. 2024. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Molecular Cancer 23:175

doi: 10.1186/s12943-024-02079-8
[21]

Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, et al. 2023. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nature Communications 14:5110

doi: 10.1038/s41467-023-40850-5
[22]

Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, et al. 2016. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proceedings of the National Academy of Sciences of the United States of America 113:E7788−E7797

doi: 10.1073/pnas.1610544113
[23]

Lu Y, Wang Q, Xue G, Bi E, Ma X, et al. 2018. Th9 cells represent a unique subset of CD4+ T cells endowed with the ability to eradicate advanced tumors. Cancer Cell 33:1048−1060.e7

doi: 10.1016/j.ccell.2018.05.004
[24]

Liu L, Bi E, Ma X, Xiong W, Qian J, et al. 2020. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nature Communications 11:5902

doi: 10.1038/s41467-020-19672-2
[25]

Labanieh L, Mackall CL. 2023. CAR immune cells: design principles, resistance and the next generation. Nature 614:635−648

doi: 10.1038/s41586-023-05707-3
[26]

Novak L, Igoucheva O, Cho S, Alexeev V. 2007. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Molecular Cancer Therapeutics 6:1755−1764

doi: 10.1158/1535-7163.MCT-06-0709
[27]

Castiglioni P, Gerloni M, Zanetti M. 2004. Genetically programmed B lymphocytes are highly efficient in inducing anti-virus protective immunity mediated by central memory CD8 T cells. Vaccine 23:699−708

doi: 10.1016/j.vaccine.2004.06.028
[28]

Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, et al. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunology 4:225−234

doi: 10.1038/ni889